逾200%的“诈尸式”暴涨！做胶卷的柯达也要向制药转型了？

英为财情2020-07-29

已经破产的昔日胶卷巨头柯达又“诈尸”了？周二，柯达表示已获得了7.65亿美元的美国政府贷款，用于仿制药生产。继富士之后，柯达也要向医药领域转型了。这则消息令柯达股票隔夜放量上涨，股价飙升203%，盘后再涨66%，令投资者瞠目结舌。继富士之后，柯达也要转型做医药？柯达将利用这笔资金生产用于仿制药的“起始原料”和“原料药（活性药物成份）”——目前，美国人消耗着全球大约40%的仿制药原料供应，但...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我想被割
2020-07-29
我想被割
冲啊，韭菜们
深井
2020-07-29
深井
同意楼上
sala001
2020-07-29
sala001
你这文章写的都没涨的快，都500%多了

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1181885578?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/3c4eea097cfac4feb0e98b384fcd378f","is_english":false,"pubTime":"2020-07-29 20:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181885578","market":"us","top_or_hot":-1,"title":"逾200%的“诈尸式”暴涨！做胶卷的柯达也要向制药转型了？","media":"英为财情","content":"<div>\n<p>已经破产的昔日胶卷巨头柯达又“诈尸”了？\n周二，柯达表示已获得了7.65亿美元的美国政府贷款，用于仿制药生产。继富士之后，柯达也要向医药领域转型了。\n这则消息令柯达股票隔夜放量上涨，股价飙升203%，盘后再涨66%，令投资者瞠目结舌。\n继富士之后，柯达也要转型做医药？\n柯达将利用这笔资金生产用于仿制药的“起始原料”和“原料药（活性药物成份）”——目前，美国人消耗着全球大约40%的仿制药原料供应，但...</p>\n\n<a href=\"https://cn.investing.com/analysis/article-200454872\">网页链接</a>\n\n</div>\n","source":"ywcq","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>逾200%的“诈尸式”暴涨！做胶卷的柯达也要向制药转型了？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n逾200%的“诈尸式”暴涨！做胶卷的柯达也要向制药转型了？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-07-29 20:49 北京时间&nbsp;&nbsp;&nbsp;<a href=https://cn.investing.com/analysis/article-200454872><strong>英为财情</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>已经破产的昔日胶卷巨头柯达又“诈尸”了？\n周二，柯达表示已获得了7.65亿美元的美国政府贷款，用于仿制药生产。继富士之后，柯达也要向医药领域转型了。\n这则消息令柯达股票隔夜放量上涨，股价飙升203%，盘后再涨66%，令投资者瞠目结舌。\n继富士之后，柯达也要转型做医药？\n柯达将利用这笔资金生产用于仿制药的“起始原料”和“原料药（活性药物成份）”——目前，美国人消耗着全球大约40%的仿制药原料供应，但...</p>\n\n<a href=\"https://cn.investing.com/analysis/article-200454872\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KODK","symbol_name":"柯达","start_time":0,"source_url":"https://cn.investing.com/analysis/article-200454872","article_id":"1181885578","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/3c4eea097cfac4feb0e98b384fcd378f"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181885578","pubTimestamp":1596026979,"columns":[],"sourceInfo":{"source_id":"ywcq","name":"英为财情"},"weMediaInfo":null,"summary":"已经破产的昔日胶卷巨头柯达又“诈尸”了？\n周二，柯达表示已获得了7.65亿美元的美国政府贷款，用于仿制药生产。继富士之后，柯达也要向医药领域转型了。\n这则消息令柯达股票隔夜放量上涨，股价飙升203%，","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"KODK":"柯达"},"translate_title":"More than 200% of the \"fake corpse\" skyrocketed! Kodak, which makes film, is also transforming into a pharmaceutical company?","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/1cda53575af2b1a556a8888df53b8698","symbols_score_info":{"KODK":0.9},"content_text":"已经破产的昔日胶卷巨头柯达又“诈尸”了？\n周二，柯达表示已获得了7.65亿美元的美国政府贷款，用于仿制药生产。继富士之后，柯达也要向医药领域转型了。\n这则消息令柯达股票隔夜放量上涨，股价飙升203%，盘后再涨66%，令投资者瞠目结舌。\n继富士之后，柯达也要转型做医药？\n柯达将利用这笔资金生产用于仿制药的“起始原料”和“原料药（活性药物成份）”——目前，美国人消耗着全球大约40%的仿制药原料供应，但只有不到10%的仿制药生产是在美国进行。按照特朗普的说法，“这是将制药业带回美国的一个突破”。\n新冠疫情暴露了美国在这方面的短板。早在疫情爆发之前，该国就已经有许多仿制药供不应求，但疫情加剧了供应的短缺，包括一些镇静剂、麻醉药，还有被特朗普所吹嘘的、争议较大的抗疟疾药物羟氯喹（福奇曾指出羟氯喹对新冠病毒无效），以及牛津大学研究发现的对新冠肺炎重症患者有效的地塞米松。\n为什么联邦政府选择了柯达？\n柯达拥有庞大的工业设施，包括1600万平方英尺的制造空间、实验室、仓库和办公室、88个批量生产反应堆，现场发电厂和蒸汽供应，同时在有机化学制造方面拥有较长时间的经验。按照设想，柯达的设施预计最多能够生产仿制药所用原料药的25%。\n同样的转型轨迹，我们也在拜耳公司 (DE:BAYGN)、3M公司 (NYSE:MMM)和富士胶片 (T:4901)等巨头身上看到过。这些公司都成功地从精细化学品行业过渡到制药业。尤其是富士胶片，同样是做胶卷的两大巨头，柯达在2012年申请破产的时候，富士胶片却成功实现了转型，将胶片业务占比降至营收的1%以下。\n事实上，富士胶片今年也参与到了新冠药物的研究竞争当中，候选药物是该公司的抗流感药物Avigan。富士胶片近年来一直在扩大其生物制药业务，2006年至2012年间进行的13起并购，有一关以上集中在医疗健康领域，其2008年收购了Toyama Chemical，这家公司所生产的Avigan也曾被用于抗击埃博拉病毒。去年，医疗保健和材料解决方案占据富士胶片总营收的43%，其目标是在未来几年来将医疗保健部门的销售额增加一倍。\n多次被迫转型无果，柯达会否重蹈覆辙？\n不过对于柯达来说，“老树开花”最终结果会如何，还不得而知。\n曾经是市值超过300亿美元的柯达，在2012年申请破产保护之后，被迫进行了一系列转型尝试，包括进军打印机、做电影胶卷，还一度与加密货币扯上了关系。\n在2018年初，柯达宣称将和Wenn Digital合作发布柯达币，并称柯达币是“一种以图片为核心的加密货币，将助力摄影师和代理机构在图像版权管理上有更多的控制权”。当时，在区块链被炒得如火如荼的背景下，这则消息也曾令柯达股票“诈尸式”起跳，当日股价翻倍。\n柯达股价走势\n但这波热点的最大作用也不过如此，之后柯达再度沉寂下去，直到现在——股价因为制药转型的消息再度回升到了2018年初的水平。在周二暴涨之前，柯达年内已经累计下跌了44%，市值只剩下1.15亿美元。\n这笔逾7亿美元的贷款可以说是柯达的救命钱。截至一季度末，柯达的现金余额只有2.1亿美元。据悉，这笔贷款的条件类似于商业贷款，需要在25年内偿还。如果转型成功，制药业务有望贡献柯达营收的30%至40%。\n但比起富士，柯达的反应还是慢了。纽约咨询公司PharmaVantage指出柯达面临的几个挑战。譬如，制药公司在向美国FDA申请批准新药上市时，必须指明使用的是哪个原料药供应商，而FDA可能需要10个月或者更长时间才能批准一个新的供应商，这意味着柯达眼下还没有直接的原料药买家；除此之外，柯达还将面临着海外供应商的激烈价格竞争，虽然美国制药商可能会更愿意与本土原料药供应商打交道，但这也要取决于价差的具体情况。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":942966578,"gmtCreate":1596038084794,"gmtModify":1704210777973,"author":{"id":"3499855986823829","authorId":"3499855986823829","name":"我想被割","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3499855986823829","authorIdStr":"3499855986823829"},"htmlText":"冲啊，韭菜们","listText":"冲啊，韭菜们","text":"冲啊，韭菜们","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/942966578","repostId":1181885578,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":942990671,"gmtCreate":1596033497493,"gmtModify":1704210721405,"author":{"id":"3556678753200118","authorId":"3556678753200118","name":"深井","avatar":"https://static.tigerbbs.com/481bf57f48dbcdd887e8de98f8d956d9","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3556678753200118","authorIdStr":"3556678753200118"},"htmlText":"同意楼上","listText":"同意楼上","text":"同意楼上","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/942990671","repostId":1181885578,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":942907591,"gmtCreate":1596033458913,"gmtModify":1704210719709,"author":{"id":"3494370642687637","authorId":"3494370642687637","name":"sala001","avatar":"https://static.tigerbbs.com/39f4f51705fcf3a337ac5be0fecf9986","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1,"idStr":"3494370642687637","authorIdStr":"3494370642687637"},"htmlText":"你这文章写的都没涨的快，都500%多了","listText":"你这文章写的都没涨的快，都500%多了","text":"你这文章写的都没涨的快，都500%多了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/942907591","repostId":1181885578,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":7,"commentSize":3,"repostSize":0,"favoriteSize":2,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181885578"}